



Oxygenta



To

Date: 27.07.2026

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636)

Sub: Outcome of Board Meeting

With reference to the subject cited this is to inform the Exchange that the Board of Directors of **Oxygenta Pharmaceutical Limited**, at its Meeting held on Monday, 27th July, 2026, at 04:00 p.m. at the corporate office of the Company, considered and approved the following:

1. Un-audited Financial Results for the quarter ended 30.06.2026. (**Attached**)
2. Limited Review Report for the quarter ended 30.06.2026. (**Attached**)
3. Appointment of M/s. PCR & Associates, Cost Accountants, as Cost Auditors of the Company for the FY 2026-27. (Details are attached as **Annexure A**)
4. Notice of the Annual General Meeting (AGM) for the financial year 2025-26.
5. Annual General Meeting for the FY 2025-26 is scheduled to be held on Friday, 21st August, 2026 at 10:30 a.m. through Video Conferencing ("VC")/ other Audio-Visual Means ("OAVM").
6. Approved the re-constitution of the POSH Committee of the Board with effect from today i.e. 27th July, 2026. (Details as annexed as **Annexure - B**)

The Meeting concluded at 5:30 p.m.


This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For Oxygenta Pharmaceutical Limited

Balasubba Reddy Mamilla
Whole-time Director
(DIN: 01998852)



OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com

Phone: 040-23073417, CIN: L24110TG1990PLC012038

Annexure – A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD-2/P/CIR/2026/1 dated January 30, 2026]

Particulars	Cost Auditor
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. PCR & Associates, Cost Accountants as Cost Auditors of the Company.
Date of appointment & Terms of appointment	Date of appointment: 27.07.2026 Terms of appointment: Appointed for the Financial Year 2026-27 at terms as recommended by the Audit Committee and approved by the Board of Directors, subject to ratification of shareholders.
Brief Profile	PCR & Associates is a leading Cost Accountancy firm rendering comprehensive professional services which include Cost Audit, Management Consultancy, Tax Consultancy, Cost Accounting Services, Manpower Management, Secretarial Services etc.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com

Phone: 040-23073417, CIN: L24110TG1990PLC012038

Annexure – B

Composition of Internal Complaints Committee (ICC)/POSH Committee

S no.	Name of the Member(s)	Designation
1.	Ms. Kurapati Divya	Presiding Officer
2.	Ms. Kuchipudi Jyothi	Internal Member
3.	Ms. B. Rajitha	Internal Member
4.	Ms. S. Chandraleka	Internal Member
5.	Ms. Yempally Sindhu	Internal Member
6.	Ms. D. Rajeswari	External Member

OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com

Phone: 040-23073417, CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED

CIN : L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad

Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@oxygentapharma.com, Phone Number: 040- 23355938

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(Rupees in Lakhs except for EPS)

S. No	Particulars		Quarter Ended			YEAR ENDED
			30-06-2026	31-03-2026	30-06-2025	31-03-2026
			(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue					
	(a)	Revenue from operations	3,699.69	4,961.40	1,513.47	11,298.19
	(b)	Other Income	2.33	17.29	16.91	28.58
	Total revenue		3,702.02	4,978.69	1,530.37	11,326.77
2	Expenses					
	(a)	Cost of materials consumed	2,340.08	4,654.43	1,565.88	11,033.85
	(b)	Changes in inventories of finished goods, work- in-progress and stock-in-trade	684.48	(334.13)	(70.34)	(820.30)
	(c)	Employee benefit expense	195.33	171.79	200.19	764.49
	(d)	Finance Costs	245.90	180.81	62.84	477.69
	(e)	Depreciation and amortisation expense	61.84	(24.11)	84.73	232.26
	(f)	Other expenses	425.10	457.88	500.69	1,856.81
	Total expenses		3,952.75	5,106.67	2,343.99	13,544.79
3	Profit before exceptional items and tax(1-2)		(250.73)	(127.97)	(813.62)	(2,218.02)
4	Exceptional Income/(expenses)		-	-	(1.18)	
5	Profit / (Loss) before tax (3+ 4)		(250.73)	(127.97)	(814.80)	(2,218.02)
6	Tax (expense)/credit					-
	a)	Current Tax	-	-	-	-
	b)	Deferred Tax	(40.36)	42.42	(204.19)	(460.86)
	Prior period Income tax adjustment					-
7	Net Profit / (Loss) for the period (5+ 6)		(210.37)	(170.39)	(610.61)	(1,757.17)
8	Other Comprehensive Income					
	(a)	(i) Items that will not be reclassified to profit or loss	-	70.99	-	70.99
		(ii) Tax on items that will not be reclassified to profit or loss	-	(10.40)	-	(18.46)
	(b)	(i) Items that will be reclassified to profit or loss	-	-	-	-
		(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income/(loss)		-	52.54	-	52.54
9	Total Comprehensive Income(7+8)		(210.37)	(117.86)	(610.61)	(1,704.63)
10	Paid-up equity share capital (face value Rs. 10/- each)		3,698.35	3,698.35	3,698.35	3,698.35
11	Earnings per equity share (of Rs.10/- each) (not annualised):					
	(a)	Basic	(0.57)	(0.45)	(1.65)	(2.86)
	(b)	Diluted	(0.57)	(0.45)	(1.65)	(2.86)




NOTES:

- 1 The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- 2 The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 27th July 2026 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township, Hyderabad, Rangareddy, Telangana, India, 500037
- 3 The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the board meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015
- 4 Total Revenue for the current quarter reported Rs. 3699.69 Lakhs compared to Rs. 1513.47 lakhs for the corresponding quarter of the previous year.
- 5 The Loss before tax for the current quarter is Rs.250.73 Lakhs compared to Loss Before tax of Rs.814.80 Lakhs for the corresponding quarter of the previous year.
- 6 The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- 7 The results for the quarter ended 30 June 2026 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
- 8 The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting.
- 9 During Q1 FY 2026-27, the Company availed financial assistance of ₹399 lakhs under the Central Government's Emergency Credit Line Guarantee Scheme (ECLGS)

Date: 27/07/2026

Place: Hyderabad



Balasubba Reddy Mamilla

[Signature]
Whole Time Director

DIN: 01998852

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of
OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended June 30, 2026("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No: 009068S



D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: **26209211CBBOAK7301**

Place: Hyderabad

Date: July 27, 2026

